AU2011240773C1 - Methods for producing viloxazine salts and novel polymorphs thereof - Google Patents
Methods for producing viloxazine salts and novel polymorphs thereof Download PDFInfo
- Publication number
- AU2011240773C1 AU2011240773C1 AU2011240773A AU2011240773A AU2011240773C1 AU 2011240773 C1 AU2011240773 C1 AU 2011240773C1 AU 2011240773 A AU2011240773 A AU 2011240773A AU 2011240773 A AU2011240773 A AU 2011240773A AU 2011240773 C1 AU2011240773 C1 AU 2011240773C1
- Authority
- AU
- Australia
- Prior art keywords
- viloxazine
- solvent
- base
- substituted
- vol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
- C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
- C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
- C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
- C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
- C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
- C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
- C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Catalysts (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32315110P | 2010-04-12 | 2010-04-12 | |
| US61/323,151 | 2010-04-12 | ||
| PCT/US2011/032013 WO2011130194A2 (en) | 2010-04-12 | 2011-04-12 | Methods for producing viloxazine salts and novel polymorphs thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2011240773A1 AU2011240773A1 (en) | 2012-11-01 |
| AU2011240773B2 AU2011240773B2 (en) | 2015-04-02 |
| AU2011240773C1 true AU2011240773C1 (en) | 2015-08-27 |
Family
ID=44065289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011240773A Active AU2011240773C1 (en) | 2010-04-12 | 2011-04-12 | Methods for producing viloxazine salts and novel polymorphs thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (7) | US9403783B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2558437B1 (cg-RX-API-DMAC7.html) |
| JP (5) | JP6196551B2 (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011240773C1 (cg-RX-API-DMAC7.html) |
| CA (4) | CA2795408C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2552166T3 (cg-RX-API-DMAC7.html) |
| MX (5) | MX2012011821A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2011130194A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2552166T3 (es) * | 2010-04-12 | 2015-11-26 | Supernus Pharmaceuticals, Inc. | Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas |
| SG11201911859QA (en) | 2017-06-16 | 2020-01-30 | Beta Pharma Inc | Pharmaceutical formulations of n-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1h-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof |
| CN108760719A (zh) * | 2018-08-17 | 2018-11-06 | 北京理工大学 | 一种利用拉曼光谱分析cl-20的晶型纯度的方法 |
| KR102927019B1 (ko) | 2021-03-18 | 2026-02-13 | 슈퍼너스 파마슈티컬스, 인크. | 치환된 몰폴린의 유도체 및 이의 용도 |
| WO2023177845A1 (en) * | 2022-03-18 | 2023-09-21 | Supernus Pharmaceuticals, Inc. | Process of making derivatives of substituted morpholines |
| WO2023248154A1 (en) * | 2022-06-22 | 2023-12-28 | Glenmark Life Sciences Limited | Process for the preparation of viloxazine hydrochloride |
| EP4317141A1 (en) | 2022-08-04 | 2024-02-07 | Curia Spain S.A.U. | Process and intermediates for the preparation of viloxazine and other 2-substituted morpholine derivatives |
| CN119707868A (zh) * | 2023-09-27 | 2025-03-28 | 西安远大科创医药科技有限公司 | 一种盐酸维洛沙嗪产品杂质及其合成方法与应用 |
| CN119707851B (zh) * | 2023-09-27 | 2026-08-11 | 远大医药(西安)有限公司 | 一种盐酸维洛沙嗪产品杂质及其合成方法与应用 |
| CN122422301A (zh) * | 2023-12-18 | 2026-07-17 | 阿斯特罗森株式会社 | (s)-维洛沙秦或其盐的改进制备方法 |
| IT202400009022A1 (it) * | 2024-04-19 | 2025-10-19 | Cambrex Profarmaco Milano S R L | Intermedi e processi per la preparazione di viloxazina |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007030366A1 (en) * | 2005-09-06 | 2007-03-15 | Smithkline Beecham Corporation | Regioselective process for preparing benzimidazole thiophenes |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1138405A (en) * | 1966-12-28 | 1969-01-01 | Ici Ltd | Morpholine derivatives |
| US3712890A (en) * | 1969-06-20 | 1973-01-23 | Ici Ltd | Process for making 2-aryloxymethyl morpholines |
| US3857839A (en) * | 1969-06-20 | 1974-12-31 | Ici Ltd | For cyclising 1-aryloxy-3 beta-substituted ethylamino-2-propanols |
| ES411826A1 (es) * | 1973-02-20 | 1976-01-01 | Liade Sa Lab | Procedimiento de obtencion de 1-ariloxi - 2 - propanolami- nas farmacologicamente activos. |
| JPS5188972A (en) | 1975-01-29 | 1976-08-04 | 22*77 indeniruokishimechiru **4 chikanmoruhorinjudotainoseiho | |
| JPS5283677A (en) | 1976-01-01 | 1977-07-12 | Yamanouchi Pharmaceut Co Ltd | Derivative of 2-(7-indenyloxymethyl)-4-substituted morpholine |
| US4711887A (en) | 1982-04-23 | 1987-12-08 | Imperial Chemical Industries Plc | Hydrazinopyridazine compounds |
| JPH06306025A (ja) * | 1992-11-30 | 1994-11-01 | Sankyo Co Ltd | ジアリールアルカン誘導体 |
| US5760069A (en) * | 1995-02-08 | 1998-06-02 | Boehringer Mannheim Pharmaceuticals Corporation-Smithkline Beecham Corporation Limited Partnership #1 | Method of treatment for decreasing mortality resulting from congestive heart failure |
| AU4949996A (en) * | 1995-03-10 | 1996-10-02 | Nycomed Salutar, Inc. | Preparation of n-arylmethyl aziridine derivatives, 1,4,7,10-tetraazacyclododecane derivatives obtained therefrom and n-arylmethyl-ethanol-amine sulphonate esters asintermediates |
| AUPO565997A0 (en) * | 1997-03-17 | 1997-04-10 | Fujisawa Pharmaceutical Co., Ltd. | Propanolamine derivatives |
| US6953855B2 (en) * | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
| DE19919153A1 (de) * | 1999-04-27 | 2000-11-02 | Consortium Elektrochem Ind | Herstellung von acrylierten flüssigkristallinen Verbindungen |
| FR2796069B3 (fr) * | 1999-07-09 | 2001-08-24 | Sanofi Synthelabo | Nouveaux procedes de preparation de derives de 2-(2- arylmorpholin-2-yl)ethanol substitues, enantiomeriquement purs, et composes intermediaires utiles dans ces procedes |
| WO2001062236A2 (en) * | 2000-02-24 | 2001-08-30 | Pharmacia & Upjohn Company | New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent |
| US20030040436A1 (en) * | 2000-10-23 | 2003-02-27 | Emerson Ralph W. | Use of benzyl ester compositions for controlling non-arthropod pest populations |
| TWI329105B (en) * | 2002-02-01 | 2010-08-21 | Rigel Pharmaceuticals Inc | 2,4-pyrimidinediamine compounds and their uses |
| US7326790B2 (en) * | 2003-05-02 | 2008-02-05 | Rigel Pharmaceuticals, Inc. | Diphenylisoxazole compounds and hydro isomers thereof |
| JP4210573B2 (ja) | 2003-10-10 | 2009-01-21 | 花王株式会社 | 置換フェノキシプロパノールアミン類 |
| JP4198183B2 (ja) * | 2004-05-27 | 2008-12-17 | ファイザー・インク | 選択的ドーパミンd3アゴニストとしてのアミノピリジン誘導体 |
| US20060118002A1 (en) * | 2004-12-03 | 2006-06-08 | Sud-Chemie Inc. | Organoclay composition containing quat mixtures |
| PE20070855A1 (es) * | 2005-12-02 | 2007-10-14 | Bayer Pharmaceuticals Corp | Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas |
| CN100415709C (zh) * | 2006-05-15 | 2008-09-03 | 西北大学 | β-(3,4-二羟基苯基)-α-羟基丙酸冰片酯、其合成方法和用途 |
| WO2008047388A2 (en) * | 2006-10-20 | 2008-04-24 | Ind-Swift Laboratories Limited | Improved process for the preparation of ranolazine |
| EP2285770B1 (en) * | 2008-06-02 | 2015-05-20 | Cipla Limited | Process for the synthesis of arformoterol |
| US20100069390A1 (en) * | 2008-09-05 | 2010-03-18 | Supernus Pharmaceuticals, Inc. | Method of treatment of attention deficit/hyperactivity disorder (ADHD) |
| US9296940B2 (en) * | 2009-12-21 | 2016-03-29 | Baker Hughes Incorporated | Dithiazine derivatives |
| ES2552166T3 (es) * | 2010-04-12 | 2015-11-26 | Supernus Pharmaceuticals, Inc. | Métodos para producir sales de viloxazina y polimorfos novedosos de las mismas |
| TWI596088B (zh) * | 2011-01-25 | 2017-08-21 | 陶氏農業科學公司 | 4-胺基-6-(經取代的苯基)吡啶甲酸酯及6-胺基-2-(經取代的苯基)-4-嘧啶羧酸酯之芳烷酯以及其等作為除草劑之用途 |
| TWI610929B (zh) * | 2012-11-21 | 2018-01-11 | 拉夸里亞創藥股份有限公司 | 多形體形式 |
-
2011
- 2011-04-12 ES ES11718804.5T patent/ES2552166T3/es active Active
- 2011-04-12 MX MX2012011821A patent/MX2012011821A/es active IP Right Grant
- 2011-04-12 JP JP2013505028A patent/JP6196551B2/ja active Active
- 2011-04-12 US US13/084,612 patent/US9403783B2/en active Active
- 2011-04-12 WO PCT/US2011/032013 patent/WO2011130194A2/en not_active Ceased
- 2011-04-12 CA CA2795408A patent/CA2795408C/en active Active
- 2011-04-12 MX MX2014010358A patent/MX357613B/es unknown
- 2011-04-12 MX MX2014010356A patent/MX347218B/es unknown
- 2011-04-12 CA CA2992219A patent/CA2992219A1/en not_active Abandoned
- 2011-04-12 MX MX2014010369A patent/MX357614B/es unknown
- 2011-04-12 EP EP11718804.5A patent/EP2558437B1/en active Active
- 2011-04-12 MX MX2014010368A patent/MX355697B/es unknown
- 2011-04-12 AU AU2011240773A patent/AU2011240773C1/en active Active
- 2011-04-12 CA CA3215310A patent/CA3215310A1/en active Pending
- 2011-04-12 CA CA3126096A patent/CA3126096C/en active Active
-
2014
- 2014-12-19 US US14/577,380 patent/US9434703B2/en active Active
-
2015
- 2015-07-15 JP JP2015141683A patent/JP2016006062A/ja active Pending
-
2016
- 2016-06-24 US US15/192,098 patent/US10005743B2/en active Active
- 2016-10-11 JP JP2016199937A patent/JP2017039754A/ja active Pending
-
2017
- 2017-11-28 JP JP2017227668A patent/JP6663413B2/ja active Active
-
2018
- 2018-05-24 US US15/988,190 patent/US10160733B2/en active Active
- 2018-11-13 US US16/189,299 patent/US20190300492A1/en not_active Abandoned
-
2019
- 2019-06-03 JP JP2019103598A patent/JP2019194191A/ja active Pending
-
2021
- 2021-08-04 US US17/393,834 patent/US20220024885A1/en not_active Abandoned
-
2025
- 2025-09-15 US US19/328,907 patent/US20260008759A1/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007030366A1 (en) * | 2005-09-06 | 2007-03-15 | Smithkline Beecham Corporation | Regioselective process for preparing benzimidazole thiophenes |
Non-Patent Citations (1)
| Title |
|---|
| JINBO, Y et al. Journal of Medicinal Chemistry. 1994, Vol. 37, No. 17, pages 2791-2791. * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260008759A1 (en) | Methods for producing viloxazine salts and novel polymorphs thereof | |
| JP2020528064A (ja) | Lfa−1拮抗薬リフィテグラストを調製および精製するためのプロセス | |
| AU2023206696A1 (en) | Method for preparing pyrrole compound and intermediate thereof | |
| WO2009047797A2 (en) | Process for the preparation of perhydroisoindole derivative | |
| CN118255769A (zh) | 一种立体异构体的制备方法及中间体 | |
| EP4219443A1 (en) | Method for preparing intermediate for synthesis of sphingosine-1-phosphate receptor agonist | |
| US20150322050A1 (en) | Efficient Process for the Preparation of Lapatinib and Salts Thereof by Means of New Intermediates | |
| EP3906235B1 (en) | Method for preparing sulfonamides drugs | |
| WO2007132990A1 (en) | Process for the preparation of chiral glycidylphthalimide in highly optical purity | |
| RU2298004C2 (ru) | Получение гидрохлорида хинаприла | |
| HK40053454B (en) | A method of preparing the isoquinoline alkaloid l-corydalmine | |
| WO2023060022A1 (en) | Synthesis of macrocyclic compounds | |
| EP2749556B1 (en) | An improved process for the preparation of pure cyamemazine and salts thereof | |
| WO2026037241A1 (zh) | 异吲哚啉类化合物制备方法、其中间体及其中间体的制备方法 | |
| CN117903138A (zh) | 一种拉罗替尼的制备方法和其应用 | |
| HK40053454A (en) | A method of preparing the isoquinoline alkaloid l-corydalmine | |
| CN112812112A (zh) | 异喹啉类生物碱左旋紫堇达明的制备方法 | |
| WO2018100565A1 (en) | Process for the preparation of indoline compound | |
| JP2007106722A5 (ja) | 18Fで標識したアミノ酸O-(2-[18F]fluoroethyl)-L-Tyrosineの前駆体の製造方法。 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAY 2015 . |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 07 MAY 2015 |
|
| FGA | Letters patent sealed or granted (standard patent) |